What is he best known for?
The fields of study he is best known for:
John C. Bell spends much of his time researching Oncolytic virus, Virology, Virus, Cancer cell and Cancer.
The study incorporates disciplines such as Ex vivo, In vivo and Viral replication in addition to Oncolytic virus.
His studies in Virology integrate themes in fields like Vaccinia and Systemic administration.
His Cancer cell research focuses on subjects like Transgene, which are linked to Hepatitis B virus, Antibody, Granulocyte and Tumor-Associated Vasculature.
The various areas that John C. Bell examines in his Cancer study include Thymidine kinase and Immune system.
His Cancer research research is multidisciplinary, incorporating perspectives in Tumor necrosis factor alpha, Cytotoxic T cell, Blockade and Immunotherapy.
His most cited work include:
- An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress (2298 citations)
- Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase (1025 citations)
- VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents (685 citations)
What are the main themes of his work throughout his whole career to date?
John C. Bell mainly investigates Oncolytic virus, Virology, Virus, Cancer research and Cancer.
His Oncolytic virus research focuses on Vesicular stomatitis virus and how it relates to Apoptosis.
John C. Bell has included themes like Cell and In vivo in his Virology study.
He combines subjects such as Ex vivo, Antibody and Cell culture with his study of Virus.
His research investigates the link between Cancer research and topics such as Immunotherapy that cross with problems in Antigen and T cell.
Cancer is a subfield of Internal medicine that he studies.
He most often published in these fields:
- Oncolytic virus (89.76%)
- Virology (49.34%)
- Virus (43.57%)
What were the highlights of his more recent work (between 2016-2021)?
- Oncolytic virus (89.76%)
- Cancer research (38.58%)
- Virus (43.57%)
In recent papers he was focusing on the following fields of study:
John C. Bell mainly focuses on Oncolytic virus, Cancer research, Virus, Immunotherapy and Immune system.
In the field of Cancer and Virology John C. Bell studies Oncolytic virus.
His research in Cancer research intersects with topics in Cancer cell, Immune checkpoint, Blockade and Breast cancer.
The Virus study combines topics in areas such as Interferon, Vaccinia, Viral vector, Vaccination and Antibody.
His biological study spans a wide range of topics, including Cytotoxic T cell, Oncology and T cell.
His Immune system research incorporates elements of Transgene and Adenocarcinoma.
Between 2016 and 2021, his most popular works were:
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade (234 citations)
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade (234 citations)
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy (125 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Oncolytic virus, Cancer research, Immunotherapy, Immune system and Cancer immunotherapy.
Research on Immunology and Virus is a part of his Oncolytic virus study.
His work deals with themes such as Cancer cell, Blockade, Vesicular stomatitis virus and Drug, which intersect with Cancer research.
John C. Bell works mostly in the field of Vesicular stomatitis virus, limiting it down to topics relating to Apoptosis and, in certain cases, Virology.
His Immunotherapy research incorporates themes from Cytotoxic T cell and Antigen.
Within one scientific family, he focuses on topics pertaining to Tumor microenvironment under Cancer immunotherapy, and may sometimes address concerns connected to Antitumor activity, Disease prognosis, Immune Modulators and Cell therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
